



CALIFORNIA TECHNOLOGY ASSESSMENT FORUM<sup>SM</sup>

## Congestive Heart Failure (CHF)

### Questions for Deliberation: October 29, 2015 Public Meeting

#### Entresto

1. For patients with Class II-IV levels of CHF and reduced ejection fraction, is the evidence adequate to demonstrate that the net health benefit of **Entresto** is greater than that of **usual care with ACE inhibitors**?  
Yes            No
2. Given the available evidence for patients with Class II-IV CHF and reduced ejection fraction, what is the care value of **Entresto** vs. **usual care with ACE inhibitors**?  
a. Low          b. Intermediate          c. High
3. Given the available evidence for patients with Class II-IV CHF and reduced ejection fraction, what is the provisional health system value of **Entresto**?  
a. Low          b. Intermediate          c. High

#### CardioMEMS

4. For patients with Class III CHF and a hospitalization in the prior 12 months, is the evidence adequate to demonstrate that the net health benefit of **CardioMEMS** is greater than **usual care**?  
Yes            No
5. Given the available evidence for patients with Class III CHF and a hospitalization in the prior 12 months, what is the care value of **CardioMEMS** vs. **usual care**?  
a. Low          b. Intermediate          c. High
6. Given the available evidence for patients with Class III CHF and a hospitalization in the prior 12 months, what is the provisional health system value of including **CardioMEMS** in CHF care management?  
a. Low          b. Intermediate          c. High